Indications
re-induction treatment of CD33-positive AML adult patients in first relapse who are not candidates for other intensive re-induction chemotherapy regimens (e.g. high-dose Ara-C) and meet at least one of the following criteria: duration of first remission <12 months, or age >60 years.
Composition
- Active substance
- gemtuzumab ozogamicin
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Mylotarg
- Active substance
- gemtuzumab ozogamicin
- ATC code
- L01XC05
- Therapeutic area
- Leukemia, Myeloid, Acute
- Marketing authorisation holder
- Wyeth Europa Ltd